Patent US5055447A successfully refreshed from Google Patents.
US5055447A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and compositions for the treatment and prevention of septic shock
Assignee: Genentech Inc
•
Filing: 1989-06-27
•
Granted: 1991-10-08
•
Expires: 2009-06-27
Abstract
Abstract Methods and compositions are provided for the treatment or prophylaxis of septic shock caused by bacteremic infection. Therapeutically and prophylactically effective doses of transforming growth factor-beta are administered to patients, either alone or in combination with another therapeutic or prophylactic agent for treating this pathologic condition. Preferably, the transforming growth factor-beta is human transforming growth factor-beta, and most preferably TGF- beta 1, TGF- beta 2, or TGF- beta 3.
Inventors
- 👤 Michael A. Palladino
- 👤 Stephen A. Sherwin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 02:40
CPC Classifications
A; A61; A61K; A61K45/00; A61K45/06; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K39/00; A61K39/395; A61P; A61P31/00; A61P31/04; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
23 words
A method comprising administering to a patient suffering from or at risk of septic shock a pharmaceutically effective amount of transforming growth factor-beta.
Claim 2
Independent Claim
23 words
A method comprising administering to a patient suffering from or at risk of septic shock a pharmaceutically effective amount of transforming growth factor-beta.
Claim 3
Dependent Claim
31 words
The method of claim 1 wherein the pharmaceutically effective amount is about 5 μg/kg to 1 mg/kg of patient body weight and the TGF-β is administered parenterally on a daily basis.
Claim 4
Dependent Claim
25 words
The method of claim 1 wherein the TGF-β is administered to a patient having a microbial infection but not yet showing symptoms of septic shock.
Claim 5
Dependent Claim
15 words
The method of claim 3 wherein the TGF-β is administered by intravenous infusion or intraperitoneally.
Claim 6
Dependent Claim
26 words
The method of claim 2 wherein the TGF-β is administered intraperitoneally to a patient having a microbial infection but not yet showing symptoms of septic shock.
Claim 7
Dependent Claim
78 words
The method of claim 1 wherein the TGF-β is administered with a pharmaceutically effective amount of mafenide acetate, an anti-microbial agent, a sympathomimetic amine, an anti-inflammatory agent. a corticosteroid, an anti-coagulant, a diuretic. an antibody against tumor necrosis factor, an antibody against lipid A, an antibody against endotoxin core glycolipid, an antibody against J5 mutant of E. coli. an antagonist to tumor necrosis factor, an antagonist to interleukin-1, or a mixture of two or more of these substances.
Claim 8
Dependent Claim
11 words
The method of claim 1 wherein the TGF-β is human TGF-β.
Claim 9
Dependent Claim
19 words
The method of claim 1 wherein the TGF-β is TGF-β 1 , TGF-β 2 , or TGF-β 3 .
Claim 10
Dependent Claim
19 words
The method of claim 7 wherein the TGF-β is TGF-β 1 , TGF-β 2 , or TGF-β 3 .
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-10-07 | 1995-04-08 | 1995-10-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-10-07 | 1999-04-08 | 1999-10-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-10-07 | 2003-04-08 | 2003-10-08 | $7700.00 | Window Closed / Lapsed |